Get in Touch

Support the UK patient organization in their engagement with NICE for the assessment of a new oncology product

  • Access Strategy, Value Communication

Client Challenge

Our client was preparing to launch a product in a competitive marketplace and sought to leverage the support of active patient organizations to advocate for its need in HTA discussions with NICE

P4A Solution

Conduct an analogue analysis based on previous HTA assessments to identify critical success factors that will enable patients / patient organisations to influence HTA decisions.

Discuss with the Patient Advocacy Group how they can engage with NICE, suggesting a variety of approaches.

Provide advance on approaches to achieve the desired outcomes and address questions from the Patient Advocacy Group as they arose including putting them in touch with suitable external (ex-NICE) advisors.

The Successful Outcome​

Offered a compliant approach for effectively engaging and supporting the Patient Advocacy Group in preparing for NICE​.

Suggested how this approach could be utilized to benefit other HTA submissions.

Need more details?

Do you want to learn more about the successful outcome for this case study? Are you interested in P4A Services or just want to say Hi?

get in touch

Explore other case studies

Understand evidence requirements beyond clinical trial data for launching an orphan drug in Türkiye & the GCC

  • Access Strategy

Optimising the PRMA potential of an orphan oncology asset in EU4 + UK and Japan

  • Price Optimisation, Access Strategy
p4a-logo-small-retina-white

We are award winning global experts in access for orphan drugs and Cell and Gene Therapies.

Twitter Instagram Youtube Linkedin

About

Services

Insights

Case Studies

Contact

P4A Services

For all access and Rare Disease related overview enquiries